Across TCGA pan-cancer cohorts, KRTAP12-1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRTAP12-1 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher KRTAP12-1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP12-1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, LUAD, and COAD are the cancer types where KRTAP12-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
LUAD	OS	Median	All	0.057	0.788	<.001	30	view →
COAD	OS	Median	All	0.159	0.799	.002	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.558	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KRTAP12-1 tumor-vs-normal RNA expression · all KRTAP12-1 data types